Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
12
×
Tags
national blog main
12
×
life sciences
biotech
boston blog main
national top stories
boston top stories
san francisco blog main
san francisco top stories
startups
national
new york blog main
new york top stories
san diego blog main
san diego top stories
cancer
deals
detroit blog main
detroit top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
investing
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
crispr therapeutics
fda
merck
pfizer
president trump
roche
san francisco
sanofi
What
today
12
×
drug
medical
new
cancer
crispr
future
annual
available
based
big
bio
biotech
cas
clinical
launch
medicines
oncology
potential
roundup
society
software
startup
technology
treatments
accelerating
acquisitions
advance
ahead
aiming
albert
ambien
ambys
american
ann
announced
approval
arbor
asco
attend
Language
unset
unknown
Current search:
photo
×
today
×
" national blog main "
×
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes
@xconomy.com
5 years ago
After Scoring New Capital, Fifth Eye Prepares to Seek FDA Approval
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs